Navigation Links
Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
Date:3/3/2008

Initial Analysis Shows Statistically Significant Pain Relief with the 2.5

and 5 mg Doses Compared to Placebo

MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today positive top-line results from its 168 patient Phase 2a clinical trial of AZ-104 (Staccato(R) loxapine) in patients with migraine headache. Migraine is a debilitating, yet common neurological disorder characterized by attacks of severe headache and autonomic nervous system dysfunction. Two doses of AZ-104, 2.5 and 5 mg, met the primary endpoint of 2-hour pain-relief compared to placebo. Alexza believes the novel, non-invasive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-104 a viable product to treat acute migraines. AZ-104 is a lower dose version of AZ-004, which is in Phase 3 clinical development for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. AZ-004 and AZ-104 are being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital in 2006.

"Loxapine is a potent antagonist at dopamine D2 receptors as well as serotonergic 5-HT2A receptors. While drugs that antagonize the D2 receptor are efficacious in treating migraine, it was proposed that the 5HT2A receptor antagonism might yield an improved adverse effect profile over drugs blocking primarily the D2 receptor. This dual mechanism of pharmacological action provided the scientific rationale to study AZ-104 in this proof-of-concept clinical trial," said James V. Cassella, PhD, Senior Vice President, Research and Development at Alexza and chairman
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... 2014 PCCA received the Autism Hope ... ) program seal for best practices in meeting ... medical practices, materials and goods that meet strict ... Children affected by autism often have unique physical ... ingredients found in food and medicine – for ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition ... and Forecasts, 2012-2018"  report to their offering. Global ... 2016. The North America accounts ... Europe claims approximately 25% (2018). ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
... EXTON, Pa., Dec. 9, 2010 Physiotherapy Associates, the ... new MS Specialty Program, which includes physical therapy services ... or alleviate the symptoms of MS for patients, available ... States. "Our new MS Specialty Program will ...
... Ambry Genetics, a global leader in genomic services ... that it has officially launched their Illumina HiSeq 2000 ... early adapter of Illumina sequencing systems since 2007 and ... (Logo:   http://photos.prnewswire.com/prnh/20090428/LA06744LOGO ) "We,ve ...
Cached Medicine Technology:Physiotherapy Associates Announces New Multiple Sclerosis Specialty Treatment Program 2Ambry Genetics Launches Illumina HiSeq 2000 Next Generation Sequencing Services 2
(Date:12/17/2014)... This prestigious award is given ... made outstanding and innovative contributions to the physical ... private practice physical therapy by the Private Practice ... On behalf of Performance Physical Therapy, Michelle Collie ... Performance accepted the award at the Private Practice, ...
(Date:12/17/2014)... December 17, 2014 Now in its ... the best of the best in senior living and ... only given to communities and agencies that have received ... site. Of the nearly 100,000 providers currently listed on ... of the SeniorAdvisor.com Best of 2015 Awards are located ...
(Date:12/17/2014)... 16, 2014 (HealthDay News) -- Poor students get more fruits ... new study finds. But, the opposite is true for ... fruits and vegetables at school may give a healthy boost ... no matter what the family income level, students all ate ... study found. The study was published recently in the ...
(Date:12/15/2014)... Grants Pass, OR (PRWEB) December 15, 2014 ... factors perceived by United States women as impacting skin ... – the “Four C’s of skin care.” Water and ... the conclusions in a recent article describing the survey ... her experience, every item in every category discussed would ...
(Date:12/15/2014)... SIMpalm, a leading mobile app ... iPhone for its client, which allows users to keep ... specialized in finding the right wine. At the ... combined sensory, chemistry and wine information. All this information ... fingerprint.” Those wines that are close counterparts to one ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2
... banned the use of vibrating condoms, saying it goes ... Limited (HLL) introduced the item throughout the country about ... Hindu hardliners described the condom was a sex toy ... protest, the ruling Bharatiya Janata Party (BJP) banned the ...
... where the potentially lethal H5N1 strain of bird flu was ... ,"All the turkeys on the farm have been ... in the area, around 1,000 birds in all," Czech veterinary ... completed today (Friday)," he added. ,The H5N1 strain of ...
... a grisly state-run Baghdad orphanage this week revealed the ... most vulnerable citizens. ,With four years of ... have begun providing vital social services at their own ... ,The images of the inside of the al-Hanan ...
... patented the technology of making new transgenic mushrooms, which ... production of commercially valuable proteins or useful human ... team of researchers including Charles Peter Romaine and Xi ... the study, scientists developed a technique to genetically modify ...
... Three Gorges Dam project across the Yangtze River will ... largest dam is already changing the local weather, claim ... data suggest that the reservoir is cooling the Yangtze ... ,Climate modeler Liguang Wu of NASA's Goddard Space ...
... mid- and upper-latitude regions are playing a smaller role ... to a study appearing in this week's issue of ... so-called missing carbon sink, concludes that intact tropical forests ... from the atmosphere, thereby partially offsetting carbon entering the ...
Cached Medicine News:Health News:Iraq's Orphans Left to the Kindness of Strangers 2Health News:Iraq's Orphans Left to the Kindness of Strangers 3Health News:New Transgenic Mushrooms Raise Hope for Mass Production of Human Drugs 2Health News:China's Three Gorges Dam Changing Local Weather: Scientists 2Health News:Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming 2Health News:Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming 3
Inquire...
QC HGB is an assayed quality control material for Hemocue analyzers. This control is a solution of stabilized human red cells and is available in 3 levels for monitoring analyzer performance at sever...
... a state of the art software package designed ... Optical Laboratory. Designed by a lens manufacturer with ... polycarbonate lenses, Optifacts is designed to help you ... not the way the software dictates., ,Designed specifically ...
VertiGraft allografts for spine surgery deliver the strength adn performance you demand in your procedures and they are backed by quality and safety standards that are unmatched in the industry....
Medicine Products: